首页 > 最新文献

Clinical and Experimental Hepatology最新文献

英文 中文
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide. glecaprevir/pibrentasvir在比替格拉韦/恩曲他滨/替诺福韦阿拉胺治疗HIV/ hcv合并感染患者中的疗效
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-29 DOI: 10.5114/ceh.2024.141752
Aleksandra Berkan-Kawińska, Anna Piekarska, Hanna Berak, Włodzimierz Mazur, Aleksander Garlicki, Magdalena Tudrujek-Zdunek, Beata Lorenc, Dorota Dybowska, Łukasz Socha, Anna Parfieniuk-Kowerda, Robert Flisiak

Aim of the study: To assess the real-life efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in HIV/HCV- positive patients treated with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF).

Material and methods: Patients were evaluated in terms of their baseline biochemical characteristics, which included platelet count, serum creatinine and bilirubin levels, alanine transaminase (ALT) activity, international normalized ratio (INR) and Model for End-Stage Liver Disease (MELD) score.The efficacy endpoint was the achievement of a sustained virologic response at posttreatment week 12 (SVR12), defined as undetectable HCV RNA 12 weeks after the scheduled end of therapy.

Results: No significant differences in baseline patient characteristics between the two study groups were observed. Patients treated with sofosbuvir/velpatasvir (SOF/VEL) were more often treatment-naïve, but the difference was not statistically significant (96.0% vs. 86.8% in GLE/PIB group, p = 0.0629). Prevalence of genotype 3 was higher in the group treated with GLE/PIB (36.9% vs. 21.8% in SOF/VEL group, p = 0.183382), while genotype 1 was more frequent in patients treated with SOF/VEL (55.4% vs. 44.7% in GLE/PIB group, p = 0.348202), but again it did not prove to be statistically significant. SVR12 rates reached 78.9% and 80.2% for GLE/PIB and SOF/VEL, respectively, in ITT analysis, and 100% and 98.8%, respectively, in modified intent-to-treat (mITT) analysis.

Conclusions: The study showed that real-life results of direct acting antiviral (DAA) therapy with GLE/PIB or SOF/VEL did not differ significantly in HIV/HCV-coinfected patients treated with B/FTC/TAF. Both regimens allowed encouraging SVR12 rates and treatment safety to be achieved, as well as tolerability, which was also comparable between the study groups.

研究目的:评估glecaprevir/pibrentasvir (GLE/PIB)治疗比替格拉韦/恩曲他滨/替诺福韦alafenamide (B/FTC/TAF)治疗HIV/HCV阳性患者的现实疗效和安全性。材料和方法:根据患者的基线生化特征进行评估,包括血小板计数、血清肌酐和胆红素水平、丙氨酸转氨酶(ALT)活性、国际标准化比率(INR)和终末期肝病模型(MELD)评分。疗效终点是在治疗后第12周达到持续的病毒学应答(SVR12),定义为在治疗计划结束后12周检测不到HCV RNA。结果:两组患者基线特征无显著差异。sofosbuvir/velpatasvir (SOF/VEL)组患者发生率更高treatment-naïve,但差异无统计学意义(GLE/PIB组96.0% vs 86.8%, p = 0.0629)。基因3型在GLE/PIB组的患病率较高(36.9% vs. SOF/VEL组的21.8%,p = 0.183382),而基因1型在SOF/VEL组的患病率较高(55.4% vs. GLE/PIB组的44.7%,p = 0.348202),但同样无统计学意义。在ITT分析中,GLE/PIB和SOF/VEL的SVR12率分别为78.9%和80.2%,在改良意向治疗(mITT)分析中,SVR12率分别为100%和98.8%。结论:研究表明,在接受B/FTC/TAF治疗的HIV/ hcv合并感染患者中,GLE/PIB或SOF/VEL直接作用抗病毒(DAA)治疗的实际效果无显著差异。两种方案均可实现令人鼓舞的SVR12率和治疗安全性,以及耐受性,这在研究组之间也具有可比性。
{"title":"Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide.","authors":"Aleksandra Berkan-Kawińska, Anna Piekarska, Hanna Berak, Włodzimierz Mazur, Aleksander Garlicki, Magdalena Tudrujek-Zdunek, Beata Lorenc, Dorota Dybowska, Łukasz Socha, Anna Parfieniuk-Kowerda, Robert Flisiak","doi":"10.5114/ceh.2024.141752","DOIUrl":"10.5114/ceh.2024.141752","url":null,"abstract":"<p><strong>Aim of the study: </strong>To assess the real-life efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in HIV/HCV- positive patients treated with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF).</p><p><strong>Material and methods: </strong>Patients were evaluated in terms of their baseline biochemical characteristics, which included platelet count, serum creatinine and bilirubin levels, alanine transaminase (ALT) activity, international normalized ratio (INR) and Model for End-Stage Liver Disease (MELD) score.The efficacy endpoint was the achievement of a sustained virologic response at posttreatment week 12 (SVR12), defined as undetectable HCV RNA 12 weeks after the scheduled end of therapy.</p><p><strong>Results: </strong>No significant differences in baseline patient characteristics between the two study groups were observed. Patients treated with sofosbuvir/velpatasvir (SOF/VEL) were more often treatment-naïve, but the difference was not statistically significant (96.0% vs. 86.8% in GLE/PIB group, <i>p</i> = 0.0629). Prevalence of genotype 3 was higher in the group treated with GLE/PIB (36.9% vs. 21.8% in SOF/VEL group, <i>p</i> = 0.183382), while genotype 1 was more frequent in patients treated with SOF/VEL (55.4% vs. 44.7% in GLE/PIB group, <i>p</i> = 0.348202), but again it did not prove to be statistically significant. SVR12 rates reached 78.9% and 80.2% for GLE/PIB and SOF/VEL, respectively, in ITT analysis, and 100% and 98.8%, respectively, in modified intent-to-treat (mITT) analysis.</p><p><strong>Conclusions: </strong>The study showed that real-life results of direct acting antiviral (DAA) therapy with GLE/PIB or SOF/VEL did not differ significantly in HIV/HCV-coinfected patients treated with B/FTC/TAF. Both regimens allowed encouraging SVR12 rates and treatment safety to be achieved, as well as tolerability, which was also comparable between the study groups.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 3","pages":"165-169"},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone marrow mesenchymal stem cell-originated exosomes suppress activation of hepatic stellate cells through the miR-144-3p/SLC7A11 axis. 骨髓间充质干细胞来源的外泌体通过miR-144-3p/SLC7A11轴抑制肝星状细胞的激活。
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.5114/ceh.2024.142898
Yanqin Hao, Rong Wang, Qing Zhou, Jiaolong Ren

Aim of the study: This study aimed to investigate the impact of bone marrow-derived mesenchymal stem cell exosomes (BMSC-Exos) on hepatic stellate cell (HSC) activation and explore the underlying molecular mechanisms in liver fibrosis.

Material and methods: BMSC-Exos were co-incubated with LPS-activated LX-2 cells. Fibrosis markers, iron content, malondialdehyde (MDA), glutathione (GSH), reactive oxygen species (ROS) levels, and ferroptosis-related proteins were assessed. The role of miR-144-3p originating from BMSC-Exos in LX-2 cell activation was studied through dual-luciferase reporter gene and RNA pull-down experiments.

Results: Treatment with BMSC-Exos up-regulated miR-144-3p in LX-2 cells, down-regulated SLC7A11, increased iron content and ROS levels, and reduced fibrosis markers and GSH. BMSC-Exos mediated ferroptosis and inhibited HSC activation by transmitting miR-144-3p targeting SLC7A11.

Conclusions: BMSC-Exos regulate SLC7A11 expression through miR-144-3p transfer, promoting ferroptosis and suppressing HSC activation in liver fibrosis.

研究目的:本研究旨在探讨骨髓间充质干细胞外泌体(BMSC-Exos)对肝星状细胞(HSC)活化的影响,并探讨肝纤维化的潜在分子机制。材料和方法:BMSC-Exos与lps活化的LX-2细胞共孵育。评估纤维化标志物、铁含量、丙二醛(MDA)、谷胱甘肽(GSH)、活性氧(ROS)水平和铁中毒相关蛋白。通过双荧光素酶报告基因和RNA下拉实验,研究源自BMSC-Exos的miR-144-3p在LX-2细胞活化中的作用。结果:BMSC-Exos治疗上调LX-2细胞中的miR-144-3p,下调SLC7A11,增加铁含量和ROS水平,降低纤维化标志物和GSH。BMSC-Exos通过传递靶向SLC7A11的miR-144-3p介导铁下垂并抑制HSC激活。结论:BMSC-Exos通过miR-144-3p的转移调节SLC7A11的表达,促进铁凋亡,抑制肝纤维化中HSC的活化。
{"title":"Bone marrow mesenchymal stem cell-originated exosomes suppress activation of hepatic stellate cells through the miR-144-3p/SLC7A11 axis.","authors":"Yanqin Hao, Rong Wang, Qing Zhou, Jiaolong Ren","doi":"10.5114/ceh.2024.142898","DOIUrl":"10.5114/ceh.2024.142898","url":null,"abstract":"<p><strong>Aim of the study: </strong>This study aimed to investigate the impact of bone marrow-derived mesenchymal stem cell exosomes (BMSC-Exos) on hepatic stellate cell (HSC) activation and explore the underlying molecular mechanisms in liver fibrosis.</p><p><strong>Material and methods: </strong>BMSC-Exos were co-incubated with LPS-activated LX-2 cells. Fibrosis markers, iron content, malondialdehyde (MDA), glutathione (GSH), reactive oxygen species (ROS) levels, and ferroptosis-related proteins were assessed. The role of miR-144-3p originating from BMSC-Exos in LX-2 cell activation was studied through dual-luciferase reporter gene and RNA pull-down experiments.</p><p><strong>Results: </strong>Treatment with BMSC-Exos up-regulated miR-144-3p in LX-2 cells, down-regulated SLC7A11, increased iron content and ROS levels, and reduced fibrosis markers and GSH. BMSC-Exos mediated ferroptosis and inhibited HSC activation by transmitting miR-144-3p targeting SLC7A11.</p><p><strong>Conclusions: </strong>BMSC-Exos regulate SLC7A11 expression through miR-144-3p transfer, promoting ferroptosis and suppressing HSC activation in liver fibrosis.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 3","pages":"197-210"},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commonly available dietary supplements, herbs and medicines - do they pose a risk for liver health? Literature review in the context of the Polish population. 常见的膳食补充剂、草药和药物——它们会对肝脏健康构成风险吗?波兰人口背景下的文献回顾。
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.5114/ceh.2024.143063
Ewa Janczewska, Barbara Janota

Liver injury resulting from the use of dietary supplements, herbs, and commonly available medications is a problem that is becoming increasingly significant due to the widespread availability and growing popularity of these products. Factors contributing to this damage may include supplements used for weight reduction, questionable quality herbs, and commonly available pain-relief and anti-inflammatory medications. Currently, the most appropriate solution to this problem appears to be prevention by patient education and medical community awareness, as well as increased oversight of the market for these types of products.

由于膳食补充剂、草药和常用药物的广泛使用和日益普及,肝脏损伤是一个日益严重的问题。造成这种损害的因素可能包括用于减肥的补充剂,质量有问题的草药,以及常用的止痛药和消炎药。目前,解决这一问题的最适当办法似乎是通过对患者进行教育和提高医学界的认识进行预防,并加强对这类产品市场的监督。
{"title":"Commonly available dietary supplements, herbs and medicines - do they pose a risk for liver health? Literature review in the context of the Polish population.","authors":"Ewa Janczewska, Barbara Janota","doi":"10.5114/ceh.2024.143063","DOIUrl":"10.5114/ceh.2024.143063","url":null,"abstract":"<p><p>Liver injury resulting from the use of dietary supplements, herbs, and commonly available medications is a problem that is becoming increasingly significant due to the widespread availability and growing popularity of these products. Factors contributing to this damage may include supplements used for weight reduction, questionable quality herbs, and commonly available pain-relief and anti-inflammatory medications. Currently, the most appropriate solution to this problem appears to be prevention by patient education and medical community awareness, as well as increased oversight of the market for these types of products.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 3","pages":"145-149"},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Varicella-zoster virus hepatitis - a rare complication of primary infection in immunocompetent children? 水痘带状疱疹病毒性肝炎——免疫功能正常儿童原发性感染的罕见并发症?
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-16 DOI: 10.5114/ceh.2024.142548
Maja Pietrzak, Maria Pokorska-Śpiewak

Aim of the study: This research aimed to investigate the incidence and course of varicella-zoster virus hepatitis in immunocompetent children.

Material and methods: Medical charts of children hospitalised between 2019 and 2022 (excluding the period of the COVID-19 pandemic) due to varicella were retrospectively analysed and compared.

Results: In total, 216 children were included in the analysis. In 24 children (11.1%) alanine aminotransferase (ALT) levels were elevated, whereas in 192 (88.9%) children, ALT levels were within the normal range. In 19 patients, ALT levels exceeded the upper limit of normal (ULN) less than twofold, in 4 patients ALT levels were elevated 2-3-fold, and in only one infant, a value 9.4× ULN was observed. None of the patients developed liver failure. The median age at the time of the diagnosis was significantly higher in the group of patients with elevated ALT - 5.5 years vs. 3 years in the group with normal ALT values (p = 0.02). The median duration of fever and hospitalization was longer by 1 day in the group with elevated ALT. Additionally, varicella lesions lasted longer in this group, 7.5 days vs. 6 days in the group with normal ALT levels (p = 0.01). Although median C-reactive protein (CRP) and procalcitonin (PCT) values did not differ, median leukocyte values were lower (p = 0.01) in the group with elevated ALT (7.3 × 103/ml vs. 8.8 × 103/ml).

Conclusions: Elevation of ALT during varicella is observed in 1 out of 10 immunocompetent patients. The course of this hepatitis is predominantly mild.

研究目的:本研究旨在调查免疫功能正常儿童水痘-带状疱疹病毒性肝炎的发病率和病程。材料与方法:回顾性分析和比较2019 - 2022年(不包括COVID-19大流行期间)因水痘住院的儿童病历。结果:共有216名儿童被纳入分析。24例(11.1%)患儿谷丙转氨酶(ALT)水平升高,192例(88.9%)患儿谷丙转氨酶水平在正常范围内。19例患者ALT水平超过正常值上限(ULN)不到2倍,4例患者ALT水平升高2-3倍,仅有1例婴儿出现9.4× ULN。没有患者出现肝功能衰竭。ALT升高组诊断时的中位年龄为5.5岁,而ALT正常组为3岁,差异有统计学意义(p = 0.02)。ALT升高组的发烧和住院时间中位数比ALT正常组长1天,水痘病变持续时间中位数比ALT正常组长7.5天(p = 0.01)。虽然中位c反应蛋白(CRP)和降钙素原(PCT)值没有差异,但ALT升高组的中位白细胞值较低(p = 0.01) (7.3 × 103/ml vs. 8.8 × 103/ml)。结论:水痘期间谷丙转氨酶升高发生率为1 / 10免疫功能正常的患者。这种肝炎的病程主要是轻微的。
{"title":"Varicella-zoster virus hepatitis - a rare complication of primary infection in immunocompetent children?","authors":"Maja Pietrzak, Maria Pokorska-Śpiewak","doi":"10.5114/ceh.2024.142548","DOIUrl":"10.5114/ceh.2024.142548","url":null,"abstract":"<p><strong>Aim of the study: </strong>This research aimed to investigate the incidence and course of varicella-zoster virus hepatitis in immunocompetent children.</p><p><strong>Material and methods: </strong>Medical charts of children hospitalised between 2019 and 2022 (excluding the period of the COVID-19 pandemic) due to varicella were retrospectively analysed and compared.</p><p><strong>Results: </strong>In total, 216 children were included in the analysis. In 24 children (11.1%) alanine aminotransferase (ALT) levels were elevated, whereas in 192 (88.9%) children, ALT levels were within the normal range. In 19 patients, ALT levels exceeded the upper limit of normal (ULN) less than twofold, in 4 patients ALT levels were elevated 2-3-fold, and in only one infant, a value 9.4× ULN was observed. None of the patients developed liver failure. The median age at the time of the diagnosis was significantly higher in the group of patients with elevated ALT - 5.5 years vs. 3 years in the group with normal ALT values (<i>p</i> = 0.02). The median duration of fever and hospitalization was longer by 1 day in the group with elevated ALT. Additionally, varicella lesions lasted longer in this group, 7.5 days vs. 6 days in the group with normal ALT levels (<i>p</i> = 0.01). Although median C-reactive protein (CRP) and procalcitonin (PCT) values did not differ, median leukocyte values were lower (<i>p</i> = 0.01) in the group with elevated ALT (7.3 × 10<sup>3</sup>/ml vs. 8.8 × 10<sup>3</sup>/ml).</p><p><strong>Conclusions: </strong>Elevation of ALT during varicella is observed in 1 out of 10 immunocompetent patients. The course of this hepatitis is predominantly mild.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 3","pages":"170-175"},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the predictive value of serum phosphate for short-term mortality in acute-on-chronic liver failure patients: An observational study at a non-transplant tertiary care centre. 评估血清磷酸盐对急性-慢性肝衰竭患者短期死亡率的预测价值:一家非移植三级医疗中心的观察性研究。
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-03-01 Epub Date: 2024-03-17 DOI: 10.5114/ceh.2024.136290
Rohit S Wagh, Shamshersingh Chauhan, Mit Shah, Yogesh Bairwa, Motij Dalai, Meghraj Ingle

Aim of the study: The gradual clinical worsening of acute-on-chronic liver failure (ACLF) leads to a high 28-day mortality rate. There are several prognostication scores for predicting early mortality in ACLF. Serum phosphate, which is the main component of adenosine tri-phosphate (ATP) synthesis, is utilized for liver synthetic functions, leading to subnormal or decreased serum phosphate levels. Hence more than normal levels of serum phosphate can be used as a marker of decreased liver cell reserve. Hence, we aimed to compare serum phosphate levels with available prognostic scores to assess mortality among ACLF patients.

Material and methods: 100 consecutive ACLF patients according to the Asia Pacific Association for Study of the Liver (APASL) definition were studied. The baseline blood workups and determination of viral bio-markers, serum phosphate, and lactate levels on days 1, 3, and 7 were carried out and prospectively followed up, and the baseline serum phosphate levels were compared with the usual scores to predict the 28-day mortality.

Results: CLIF-SOFA (accuracy 76-91%) followed by CLIF-C score (accuracy 73-84%) and AARC score (accuracy 70-85%) had the statistically significantly highest accuracy as compared with CTP, MELD, and MELD-Na on all three days. Serum phosphate values (accuracy 69-86%) on all three days were not better than the CLIF-SOFA score but better than all other prognostic scores on days 3 and 7.

Conclusions: The high serum phosphate levels on day 3 with a value of more than 6.4 mg/dl showed almost comparable accuracy with CLIF-SOFA for screening short-term mortality. Hence serum phosphate measurement can be used as a simple bedside laboratory investigation to predict mortality in ACLF patients and early interventions in low-resource settings.

研究目的急性慢性肝衰竭(ACLF)的临床症状逐渐恶化,导致 28 天的死亡率很高。目前有几种预后评分方法可预测急性慢性肝衰竭的早期死亡率。血清磷酸盐是合成三磷酸腺苷(ATP)的主要成分,被用于肝脏合成功能,导致血清磷酸盐水平低于正常或下降。因此,血清磷酸盐水平高于正常值可作为肝细胞储备减少的标志。因此,我们旨在将血清磷酸盐水平与现有的预后评分进行比较,以评估 ACLF 患者的死亡率。结果:CLIF-SOFA(准确率为76%)、CLIF-SOFA(准确率为76%)、CLIF-SOFA(准确率为76%)、CLIF-SOFA(准确率为76%)、CLIF-SOFA(准确率为76%)、CLIF-SOFA(准确率为76%)、CLIF-SOFA(准确率为76%)、CLIF-SOFA(准确率为76%):结果:与 CTP、MELD 和 MELD-Na 相比,CLIF-SOFA(准确率 76-91%)、CLIF-C 评分(准确率 73-84%)和 AARC 评分(准确率 70-85%)在所有三天中的准确率都明显最高。所有三天的血清磷酸盐值(准确率为 69-86%)均不优于 CLIF-SOFA 评分,但优于第 3 天和第 7 天的所有其他预后评分:在筛查短期死亡率方面,第 3 天血清磷酸盐水平较高且大于 6.4 mg/dl 的准确性几乎与 CLIF-SOFA 相当。因此,血清磷酸盐测量可作为一项简单的床边实验室检查,用于预测 ACLF 患者的死亡率,并在资源匮乏的环境中进行早期干预。
{"title":"Assessing the predictive value of serum phosphate for short-term mortality in acute-on-chronic liver failure patients: An observational study at a non-transplant tertiary care centre.","authors":"Rohit S Wagh, Shamshersingh Chauhan, Mit Shah, Yogesh Bairwa, Motij Dalai, Meghraj Ingle","doi":"10.5114/ceh.2024.136290","DOIUrl":"10.5114/ceh.2024.136290","url":null,"abstract":"<p><strong>Aim of the study: </strong>The gradual clinical worsening of acute-on-chronic liver failure (ACLF) leads to a high 28-day mortality rate. There are several prognostication scores for predicting early mortality in ACLF. Serum phosphate, which is the main component of adenosine tri-phosphate (ATP) synthesis, is utilized for liver synthetic functions, leading to subnormal or decreased serum phosphate levels. Hence more than normal levels of serum phosphate can be used as a marker of decreased liver cell reserve. Hence, we aimed to compare serum phosphate levels with available prognostic scores to assess mortality among ACLF patients.</p><p><strong>Material and methods: </strong>100 consecutive ACLF patients according to the Asia Pacific Association for Study of the Liver (APASL) definition were studied. The baseline blood workups and determination of viral bio-markers, serum phosphate, and lactate levels on days 1, 3, and 7 were carried out and prospectively followed up, and the baseline serum phosphate levels were compared with the usual scores to predict the 28-day mortality.</p><p><strong>Results: </strong>CLIF-SOFA (accuracy 76-91%) followed by CLIF-C score (accuracy 73-84%) and AARC score (accuracy 70-85%) had the statistically significantly highest accuracy as compared with CTP, MELD, and MELD-Na on all three days. Serum phosphate values (accuracy 69-86%) on all three days were not better than the CLIF-SOFA score but better than all other prognostic scores on days 3 and 7.</p><p><strong>Conclusions: </strong>The high serum phosphate levels on day 3 with a value of more than 6.4 mg/dl showed almost comparable accuracy with CLIF-SOFA for screening short-term mortality. Hence serum phosphate measurement can be used as a simple bedside laboratory investigation to predict mortality in ACLF patients and early interventions in low-resource settings.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 1","pages":"20-29"},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nicotine promotes development of bile duct ligation-induced liver fibrosis by increasing expression of nicotinic acetylcholine receptors in rats. 尼古丁通过增加大鼠尼古丁乙酰胆碱受体的表达,促进胆管结扎诱发的肝纤维化的发展。
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-03-01 Epub Date: 2024-03-15 DOI: 10.5114/ceh.2024.136227
Khalil Hajiasgharzadeh, Parviz Shahabi, Elham Karimi-Sales, Mohammad Reza Alipour

Aim of the study: Liver fibrosis and cigarette smoking seem to be directly linked. Nicotine, as an agonist of nicotinic acetylcholine receptors (nAChRs), induces many downstream signaling pathways. The pathways through which nicotine affects the process of liver fibrosis have not been clarified. The present study aimed to investigate the nicotine-induced effects on fibrosis progression in cholestatic rats.

Material and methods: First, the Wistar rats were subjected to sham or bile duct ligation (BDL) surgery. The rats were treated with low and high doses of nicotine (1 or 10 mg/kg) for three weeks. They were monitored for their body weights before and 21 days after BDL. Also, spleens were weighed to calculate the spleen/body weight ratio. Ductular proliferation and fibrosis were evaluated using hematoxylin and eosin (H&E) as well as Masson's trichrome staining. The mRNA expression of α4nAChR, α7nAChR, and fibrosis gene α-smooth muscle actin (α-SMA) was measured by real-time PCR.

Results: The findings showed that nicotine promotes the development of BDL-induced liver fibrosis. The ratio of spleen/body weight was significantly affected by nicotine exposure. H&E and Masson's trichrome staining showed that the level of liver fibrosis was higher in the cholestatic BDL groups, and this effect was significantly augmented in the nicotine-treated rats. Also, α4nAChR, α7nAChR, and α-SMA expression was observed in the BDL rats and increased following nicotine treatment.

Conclusions: The activation of nAChR triggers biliary proliferation and liver fibrosis. Studying the intracellular mechanism of nicotine and alteration in the expression of nicotinic receptors following nicotine exposure can be useful both in diagnosing nicotine-related diseases and finding new treatment strategies.

研究目的肝纤维化似乎与吸烟直接相关。尼古丁作为烟碱乙酰胆碱受体(nAChRs)的激动剂,会诱导许多下游信号通路。尼古丁影响肝纤维化过程的途径尚未明确。本研究旨在探讨尼古丁对胆汁淤积性大鼠肝纤维化进程的影响:首先,对 Wistar 大鼠进行假手术或胆管结扎(BDL)手术。用低剂量和高剂量尼古丁(1 或 10 毫克/千克)对大鼠进行为期三周的治疗。在胆管结扎术前和术后 21 天监测大鼠的体重。此外,还对脾脏进行称重,以计算脾脏/体重比。使用苏木精和伊红(H&E)以及马森三色染色法评估导管增生和纤维化。实时 PCR 检测了α4nAChR、α7nAChR 和纤维化基因α-平滑肌肌动蛋白(α-SMA)的 mRNA 表达:结果:研究结果表明,尼古丁会促进BDL诱导的肝纤维化的发展。尼古丁暴露对脾脏/体重比值有显著影响。H&E和Masson三色染色显示,胆汁淤积型BDL组的肝纤维化程度较高,而尼古丁处理组的肝纤维化程度明显升高。此外,在 BDL 大鼠中还观察到 α4nAChR、α7nAChR 和 α-SMA 的表达,并在尼古丁处理后增加:结论:nAChR的激活会引发胆汁增生和肝纤维化。研究尼古丁的细胞内机制以及尼古丁暴露后尼古丁受体表达的变化,有助于诊断尼古丁相关疾病和寻找新的治疗策略。
{"title":"Nicotine promotes development of bile duct ligation-induced liver fibrosis by increasing expression of nicotinic acetylcholine receptors in rats.","authors":"Khalil Hajiasgharzadeh, Parviz Shahabi, Elham Karimi-Sales, Mohammad Reza Alipour","doi":"10.5114/ceh.2024.136227","DOIUrl":"10.5114/ceh.2024.136227","url":null,"abstract":"<p><strong>Aim of the study: </strong>Liver fibrosis and cigarette smoking seem to be directly linked. Nicotine, as an agonist of nicotinic acetylcholine receptors (nAChRs), induces many downstream signaling pathways. The pathways through which nicotine affects the process of liver fibrosis have not been clarified. The present study aimed to investigate the nicotine-induced effects on fibrosis progression in cholestatic rats.</p><p><strong>Material and methods: </strong>First, the Wistar rats were subjected to sham or bile duct ligation (BDL) surgery. The rats were treated with low and high doses of nicotine (1 or 10 mg/kg) for three weeks. They were monitored for their body weights before and 21 days after BDL. Also, spleens were weighed to calculate the spleen/body weight ratio. Ductular proliferation and fibrosis were evaluated using hematoxylin and eosin (H&E) as well as Masson's trichrome staining. The mRNA expression of α4nAChR, α7nAChR, and fibrosis gene α-smooth muscle actin (α-SMA) was measured by real-time PCR.</p><p><strong>Results: </strong>The findings showed that nicotine promotes the development of BDL-induced liver fibrosis. The ratio of spleen/body weight was significantly affected by nicotine exposure. H&E and Masson's trichrome staining showed that the level of liver fibrosis was higher in the cholestatic BDL groups, and this effect was significantly augmented in the nicotine-treated rats. Also, α4nAChR, α7nAChR, and α-SMA expression was observed in the BDL rats and increased following nicotine treatment.</p><p><strong>Conclusions: </strong>The activation of nAChR triggers biliary proliferation and liver fibrosis. Studying the intracellular mechanism of nicotine and alteration in the expression of nicotinic receptors following nicotine exposure can be useful both in diagnosing nicotine-related diseases and finding new treatment strategies.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 1","pages":"62-71"},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Syphilitic hepatitis. 梅毒性肝炎
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-03-01 Epub Date: 2024-03-12 DOI: 10.5114/ceh.2024.136235
Łukasz Supronowicz, Magdalena Rogalska

Syphilis is a sexually transmitted multisystemic disease known as "the great imitator" due to its variable presentations. Despite being preventable and curable, it still constitutes a major health problem. Hepatic manifestation of syphilis is usually mild cholestatic liver injury but in very rare cases can become fulminant. Moreover, syphilitic hepatitis, known for several decades, is considered rare but is probably under-diagnosed. Given the significant morbidity associated with a missed diagnosis, syphilitic hepatitis should be taken into account as an element of differential diagnosis in patients with unexplained elevation of liver enzymes.

梅毒是一种通过性传播的多系统疾病,因其表现形式多变而被称为 "伟大的模仿者"。尽管梅毒是可以预防和治愈的,但它仍然是一个重大的健康问题。梅毒的肝脏表现通常是轻度胆汁淤积性肝脏损伤,但在极少数情况下也会发展为急性肝损伤。此外,梅毒性肝炎已为人所知数十年,被认为是罕见病,但可能诊断不足。鉴于漏诊会导致严重的发病率,对于不明原因肝酶升高的患者,梅毒性肝炎应作为鉴别诊断的一个因素加以考虑。
{"title":"Syphilitic hepatitis.","authors":"Łukasz Supronowicz, Magdalena Rogalska","doi":"10.5114/ceh.2024.136235","DOIUrl":"10.5114/ceh.2024.136235","url":null,"abstract":"<p><p>Syphilis is a sexually transmitted multisystemic disease known as \"the great imitator\" due to its variable presentations. Despite being preventable and curable, it still constitutes a major health problem. Hepatic manifestation of syphilis is usually mild cholestatic liver injury but in very rare cases can become fulminant. Moreover, syphilitic hepatitis, known for several decades, is considered rare but is probably under-diagnosed. Given the significant morbidity associated with a missed diagnosis, syphilitic hepatitis should be taken into account as an element of differential diagnosis in patients with unexplained elevation of liver enzymes.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 1","pages":"9-13"},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variables associated with antibiotic administration for performing paracentesis among patients with ascites in a community hospital. 社区医院腹水患者在进行腹腔穿刺术时使用抗生素的相关变量。
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-03-01 Epub Date: 2024-03-28 DOI: 10.5114/ceh.2024.136215
Nikisha Pandya, Nitin Pendyala, Joshua Fogel, Pawel Szurnicki, Mohammad Choudhry, Amanda Eng, Muhammad Abdullah

Aim of the study: Early paracentesis before antibiotic administration reduces morbidity and mortality in patients with decompensated cirrhosis. We studied the association of variables with antibiotic administration before or after performing paracentesis.

Material and methods: This was a retrospective study of 137 patients with ascites secondary to cirrhosis admitted to a community hospital in New York City. Predictor variables were demographic, disease-related, admission timing, and serum measurement.

Results: We found a significantly increased relative risk for performing paracentesis after antibiotic administration for those admitted at night (relative risk ratio [RRR] = 3.01, 95% CI: 1.02-8.85, p = 0.046). Demographic, disease-related, and serum measurement variables were not significantly associated with performing paracentesis or order of antibiotic administration. Also, increased body mass index was significantly associated with decreased relative risk for paracentesis not done (RRR = 0.84, 95% CI: 0.74-0.96, p = 0.01).

Conclusions: In conclusion, there was increased relative risk for performing paracentesis after antibiotic administration for patients admitted at night. We recommend ongoing resident and hospitalist training to maintain competency in bedside procedures such as paracentesis for patients with cirrhosis. Also, increased staffing or the presence of a resident/hospitalist led interventional team during night shifts may also help optimize the rates of timely paracentesis.

研究目的肝硬化失代偿期患者在使用抗生素前尽早进行旁路穿刺可降低发病率和死亡率。我们研究了在进行腹腔穿刺术之前或之后使用抗生素的相关变量:这是一项回顾性研究,研究对象是纽约市一家社区医院收治的 137 名肝硬化腹水患者。预测变量包括人口统计学变量、疾病相关变量、入院时间变量和血清测量变量:我们发现,夜间入院的患者在使用抗生素后进行腹腔穿刺的相对风险明显增加(相对风险比 [RRR] = 3.01,95% CI:1.02-8.85,P = 0.046)。人口统计学变量、疾病相关变量和血清测量变量与腹腔穿刺术或抗生素用药顺序无显著相关性。此外,体重指数增加与未进行旁路穿刺的相对风险降低有显著相关性(RRR = 0.84,95% CI:0.74-0.96,p = 0.01):总之,夜间入院的患者在使用抗生素后进行旁路穿刺的相对风险增加。我们建议对住院医师和住院医生进行持续培训,以保持他们在床旁操作(如肝硬化患者的旁路穿刺术)方面的能力。此外,在夜班期间增加人手或由住院医师/医院医师领导的介入团队也有助于优化及时进行旁路穿刺术的比率。
{"title":"Variables associated with antibiotic administration for performing paracentesis among patients with ascites in a community hospital.","authors":"Nikisha Pandya, Nitin Pendyala, Joshua Fogel, Pawel Szurnicki, Mohammad Choudhry, Amanda Eng, Muhammad Abdullah","doi":"10.5114/ceh.2024.136215","DOIUrl":"10.5114/ceh.2024.136215","url":null,"abstract":"<p><strong>Aim of the study: </strong>Early paracentesis before antibiotic administration reduces morbidity and mortality in patients with decompensated cirrhosis. We studied the association of variables with antibiotic administration before or after performing paracentesis.</p><p><strong>Material and methods: </strong>This was a retrospective study of 137 patients with ascites secondary to cirrhosis admitted to a community hospital in New York City. Predictor variables were demographic, disease-related, admission timing, and serum measurement.</p><p><strong>Results: </strong>We found a significantly increased relative risk for performing paracentesis after antibiotic administration for those admitted at night (relative risk ratio [RRR] = 3.01, 95% CI: 1.02-8.85, <i>p</i> = 0.046). Demographic, disease-related, and serum measurement variables were not significantly associated with performing paracentesis or order of antibiotic administration. Also, increased body mass index was significantly associated with decreased relative risk for paracentesis not done (RRR = 0.84, 95% CI: 0.74-0.96, <i>p</i> = 0.01).</p><p><strong>Conclusions: </strong>In conclusion, there was increased relative risk for performing paracentesis after antibiotic administration for patients admitted at night. We recommend ongoing resident and hospitalist training to maintain competency in bedside procedures such as paracentesis for patients with cirrhosis. Also, increased staffing or the presence of a resident/hospitalist led interventional team during night shifts may also help optimize the rates of timely paracentesis.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 1","pages":"47-52"},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contrast-enhanced ultrasonography as a method of monitoring focal liver lesions - initial report. 超声造影作为一种监测局灶性肝脏病变的方法——初步报告。
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-03-01 Epub Date: 2024-06-11 DOI: 10.5114/ceh.2024.140449
Adam Dobek, Mateusz Kobierecki, Patryk Wieczorek, Oliwia Grząsiak, Wojciech Ciesielski, Adam Fabisiak, Ludomir Stefańczyk

Aim of the study: Hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH) are benign liver tumors. Hepatocellular adenoma has potential for growth, metaplasia and rupture; therefore, it should be monitored long term. In the current guidelines biopsy is not recommended in the standard diagnostic protocol. Magnetic resonance imaging (MRI) is accepted as standard in diagnostics and monitoring of these lesions. The aim of the study was to compare contrast-enhanced ultrasound (CEUS) and MRI in imaging of these tumors and determine whether CEUS can be useful in monitoring benign liver tumors.

Material and methods: A retrospective analysis of 47 patients with HCA (32 tumors) and FNH (27 tumors) was carried out. A comparison between MRI and CEUS in predicting malignant transformation was performed.

Results: A similar tumor enhancement profile to unchanged liver parenchyma was observed in both groups. The difference in the arterial phase was on average up to 30 dB. After 20-30 s, the enhancement of HCA and FNH in relation to the liver parenchyma was similar (difference up to 4-5 dB). Homogeneity and equalization of the tumor to background enhancement was observed until the end of the examination. The discriminative feature is the presence of a non-contrasting central fibrous scar observed in both imaging methods in the FNH group.

Conclusions: CEUS can be a promising method in monitoring focal liver lesions due to low cost and low risk of complications. It is essential to analyze the early arterial phase up to 30 s to demonstrate homogeneous enhancement of the tumor and potential presence of a wash-out effect during later phases of examination.

研究目的:肝细胞腺瘤(HCA)和局灶性结节性增生(FNH)是肝脏良性肿瘤。肝细胞腺瘤有生长、化生和破裂的可能;因此,应长期监测。在目前的指南中,活检不推荐作为标准诊断方案。磁共振成像(MRI)是公认的诊断和监测这些病变的标准。本研究的目的是比较超声造影(CEUS)和MRI对这些肿瘤的成像效果,并确定超声造影是否可用于监测良性肝脏肿瘤。材料与方法:回顾性分析47例HCA(32个肿瘤)和FNH(27个肿瘤)患者。比较MRI与超声造影预测恶性转化的效果。结果:两组患者的肿瘤增强特征与未改变的肝实质相似。动脉期的差异平均可达30db。20 ~ 30s后,HCA和FNH相对于肝实质的增强相似(差异可达4 ~ 5db)。观察到肿瘤与背景增强的均匀性和均衡性,直到检查结束。鉴别特征是在FNH组两种成像方法中观察到的非对比性中心纤维瘢痕的存在。结论:超声造影成本低,并发症风险低,是一种很有前途的肝局灶性病变监测方法。有必要分析早期动脉期至30秒,以证明肿瘤的均匀增强和在检查后期可能存在的冲洗效应。
{"title":"Contrast-enhanced ultrasonography as a method of monitoring focal liver lesions - initial report.","authors":"Adam Dobek, Mateusz Kobierecki, Patryk Wieczorek, Oliwia Grząsiak, Wojciech Ciesielski, Adam Fabisiak, Ludomir Stefańczyk","doi":"10.5114/ceh.2024.140449","DOIUrl":"10.5114/ceh.2024.140449","url":null,"abstract":"<p><strong>Aim of the study: </strong>Hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH) are benign liver tumors. Hepatocellular adenoma has potential for growth, metaplasia and rupture; therefore, it should be monitored long term. In the current guidelines biopsy is not recommended in the standard diagnostic protocol. Magnetic resonance imaging (MRI) is accepted as standard in diagnostics and monitoring of these lesions. The aim of the study was to compare contrast-enhanced ultrasound (CEUS) and MRI in imaging of these tumors and determine whether CEUS can be useful in monitoring benign liver tumors.</p><p><strong>Material and methods: </strong>A retrospective analysis of 47 patients with HCA (32 tumors) and FNH (27 tumors) was carried out. A comparison between MRI and CEUS in predicting malignant transformation was performed.</p><p><strong>Results: </strong>A similar tumor enhancement profile to unchanged liver parenchyma was observed in both groups. The difference in the arterial phase was on average up to 30 dB. After 20-30 s, the enhancement of HCA and FNH in relation to the liver parenchyma was similar (difference up to 4-5 dB). Homogeneity and equalization of the tumor to background enhancement was observed until the end of the examination. The discriminative feature is the presence of a non-contrasting central fibrous scar observed in both imaging methods in the FNH group.</p><p><strong>Conclusions: </strong>CEUS can be a promising method in monitoring focal liver lesions due to low cost and low risk of complications. It is essential to analyze the early arterial phase up to 30 s to demonstrate homogeneous enhancement of the tumor and potential presence of a wash-out effect during later phases of examination.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 2","pages":"120-128"},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biological rhythms of the liver. 肝脏的生物节律
IF 1.5 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-03-01 Epub Date: 2024-03-15 DOI: 10.5114/ceh.2024.136220
Anatol Panasiuk, Mirosław Tarasewicz, Albert Chodowiec, Anna Łokić, Kacper Gan

The biological rhythm is a fundamental aspect of an organism, regulating many physiological processes. This study focuses on the analysis of the molecular basis of circadian rhythms and its impact on the functioning of the liver. The regulation of biological rhythms is carried out by the clock system, which consists of the central clock and peripheral clocks. The central clock is located in the suprachiasmatic nucleus (SCN) of the hypothalamus and is regulated by signals received from the retinal pathway. The SCN regulates the circadian rhythm of the entire body through its indirect influence on the peripheral clocks. In turn, the peripheral clocks can maintain their own rhythm, independent of the SCN, by creating special feedback loops between transcriptional and translational factors. The main protein families involved in these processes are CLOCK, BMAL, PER and CRY. Disorders in the expression of these factors have a significant impact on the functioning of the liver. In such cases lipid metabolism, cholesterol metabolism, bile acid metabolism, alcohol metabolism, and xenobiotic detoxification can be significantly affected. Clock dysfunctions contribute to the pathogenesis of various disorders, including fatty liver disease, liver cirrhosis and different types of cancer. Therefore understanding circadian rhythm can have significant implications for the therapy of many liver diseases, as well as the development of new preventive and treatment strategies.

生物节律是生物体的一个基本方面,调节着许多生理过程。本研究主要分析昼夜节律的分子基础及其对肝脏功能的影响。生物节律由时钟系统进行调节,时钟系统由中央时钟和外周时钟组成。中枢时钟位于下丘脑的丘上核(SCN),受视网膜通路发出的信号调节。SCN 通过对外周时钟的间接影响来调节整个身体的昼夜节律。反过来,外周时钟也可以通过在转录因子和翻译因子之间建立特殊的反馈回路来维持自身的节律,而不依赖于 SCN。参与这些过程的主要蛋白质家族包括 CLOCK、BMAL、PER 和 CRY。这些因子的表达紊乱会对肝脏的功能产生重大影响。在这种情况下,脂质代谢、胆固醇代谢、胆汁酸代谢、酒精代谢和异生物解毒都会受到严重影响。时钟功能障碍是脂肪肝、肝硬化和各种癌症等各种疾病的发病机理之一。因此,了解昼夜节律对治疗多种肝病以及开发新的预防和治疗策略具有重要意义。
{"title":"Biological rhythms of the liver.","authors":"Anatol Panasiuk, Mirosław Tarasewicz, Albert Chodowiec, Anna Łokić, Kacper Gan","doi":"10.5114/ceh.2024.136220","DOIUrl":"10.5114/ceh.2024.136220","url":null,"abstract":"<p><p>The biological rhythm is a fundamental aspect of an organism, regulating many physiological processes. This study focuses on the analysis of the molecular basis of circadian rhythms and its impact on the functioning of the liver. The regulation of biological rhythms is carried out by the clock system, which consists of the central clock and peripheral clocks. The central clock is located in the suprachiasmatic nucleus (SCN) of the hypothalamus and is regulated by signals received from the retinal pathway. The SCN regulates the circadian rhythm of the entire body through its indirect influence on the peripheral clocks. In turn, the peripheral clocks can maintain their own rhythm, independent of the SCN, by creating special feedback loops between transcriptional and translational factors. The main protein families involved in these processes are CLOCK, BMAL, PER and CRY. Disorders in the expression of these factors have a significant impact on the functioning of the liver. In such cases lipid metabolism, cholesterol metabolism, bile acid metabolism, alcohol metabolism, and xenobiotic detoxification can be significantly affected. Clock dysfunctions contribute to the pathogenesis of various disorders, including fatty liver disease, liver cirrhosis and different types of cancer. Therefore understanding circadian rhythm can have significant implications for the therapy of many liver diseases, as well as the development of new preventive and treatment strategies.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"10 1","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Experimental Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1